PKR (Protein Kinase R), also known as EIF2AK2 (Eukaryotic Translation Initiation Factor 2-Alpha Kinase 2), is a 98 kDa serine/threonine protein kinase that plays critical roles in the cellular stress response, particularly in the integrated stress response (ISR). PKR is activated by double-stranded RNA (dsRNA), endoplasmic reticulum stress, oxidative stress, and various pathological stimuli, leading to phosphorylation of the translation initiation factor eIF2α and global translational repression[@dey2005]. In the nervous system, PKR has emerged as a key regulator of neuroinflammation, synaptic plasticity, and neuronal survival, with mounting evidence implicating its dysregulation in the pathogenesis of [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), amyotrophic lateral sclerosis (ALS), and other neurodegenerative disorders[@peel2011].
PKR is one of four eIF2α kinases that comprise the integrated stress response pathway, each activated by distinct stress stimuli. While PKR was originally characterized for its role in antiviral defense—its activation by dsRNA during viral infection leads to inhibition of viral protein synthesis—subsequent research has revealed broader functions in cellular homeostasis, synaptic plasticity, and neurodegeneration. The kinase is widely expressed in the brain, with particularly high levels in neurons and microglia, where it participates in both cell-autonomous and non-cell-autonomous pathogenic processes.
PKR (Protein Kinase R), also known as EIF2AK2 (Eukaryotic Translation Initiation Factor 2-Alpha Kinase 2), is a 98 kDa serine/threonine protein kinase that plays critical roles in the cellular stress response, particularly in the integrated stress response (ISR). PKR is activated by double-stranded RNA (dsRNA), endoplasmic reticulum stress, oxidative stress, and various pathological stimuli, leading to phosphorylation of the translation initiation factor eIF2α and global translational repression[@dey2005]. In the nervous system, PKR has emerged as a key regulator of neuroinflammation, synaptic plasticity, and neuronal survival, with mounting evidence implicating its dysregulation in the pathogenesis of [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), amyotrophic lateral sclerosis (ALS), and other neurodegenerative disorders[@peel2011].
PKR is one of four eIF2α kinases that comprise the integrated stress response pathway, each activated by distinct stress stimuli. While PKR was originally characterized for its role in antiviral defense—its activation by dsRNA during viral infection leads to inhibition of viral protein synthesis—subsequent research has revealed broader functions in cellular homeostasis, synaptic plasticity, and neurodegeneration. The kinase is widely expressed in the brain, with particularly high levels in neurons and microglia, where it participates in both cell-autonomous and non-cell-autonomous pathogenic processes.
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">PKR (Protein Kinase R)</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Protein Kinase R (PKR)</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>EIF2AK2</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P19559](https://www.uniprot.org/uniprot/P19559)</td></tr>
<tr><td><strong>PDB Structures</strong></td><td>2E7O, 3U1U, 4N0M</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>98 kDa</td></tr>
<tr><td><strong>Amino Acids</strong></td><td>551</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cytoplasm, Nucleus</td></tr>
<tr><td><strong>Protein Family</strong></td><td>eIF2α kinase family</td></tr>
<tr><td><strong>Brain Expression</strong></td><td>High in cortex, hippocampus, cerebellum, basal ganglia</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">3 edges</a></td>
</tr>
</table>
</div>
The discovery of PKR dates back to the 1970s when it was first identified as a kinase activated by dsRNA during viral infections. Subsequent decades of research have revealed PKR as a multifunctional protein with roles extending far beyond antiviral immunity. In the nervous system, PKR participates in fundamental processes including translational control during stress, synaptic plasticity, and the modulation of neuroinflammatory responses. The protein's involvement in these diverse functions, combined with its activation by pathological stimuli present in neurodegenerative diseases, has positioned PKR as a molecule of significant interest for understanding disease mechanisms and developing therapeutic interventions.
PKR's enzymatic activity is tightly regulated through multiple mechanisms. In the basal state, the protein exists in an autoinhibited conformation that prevents kinase activity. Upon binding to dsRNA or other activators, PKR undergoes conformational changes that release the kinase domain from inhibition, leading to autophosphorylation and full activation. This activation mechanism ensures that PKR responds specifically to pathological or stress-related stimuli while remaining quiescent under normal conditions. However, in neurodegenerative diseases, chronic activation of PKR contributes to pathological processes including synaptic dysfunction, tau hyperphosphorylation, and neuroinflammation.
PKR is a 551-amino acid protein with a modular architecture consisting of distinct functional domains. The N-terminal regulatory region contains two double-stranded RNA binding motifs (dsRBMs, residues 1-170) that mediate dsRNA recognition and PKR activation. These motifs adopt an RNA-binding fold that recognizes the characteristic helical structure of dsRNA but not single-stranded RNA. The affinity and specificity of dsRNA binding by these domains determines the sensitivity of PKR activation to different cellular RNAs.
The C-terminal kinase domain (residues 257-551) contains the catalytic core of PKR, including the ATP-binding pocket and the activation loop that undergoes phosphorylation during activation. The kinase domain shares structural features with other serine/threonine kinases, including a bilobal architecture with a smaller N-terminal lobe containing the glycine-rich loop and a larger C-terminal lobe that provides the substrate-binding surface. The kinase domain also contains regulatory elements that control activity, including the linker region connecting it to the N-terminal dsRBMs.
PKR activation is a multistep process initiated by dsRNA binding to the N-terminal dsRBMs. dsRNA binding induces dimerization of PKR, bringing the kinase domains into proximity for trans-autophosphorylation. This dimerization-dependent activation ensures that PKR responds specifically to dsRNA signals rather than spurious activation. The autophosphorylation events occur primarily in the activation loop, leading to a conformational change that stabilizes the active form of the enzyme.
Beyond dsRNA, PKR can be activated by other stimuli relevant to neurodegenerative disease, including:
The primary downstream target of PKR is the translation initiation factor eIF2α. Phosphorylation of eIF2α at serine 51 converts eIF2 from a substrate into a competitive inhibitor of its guanine nucleotide exchange factor eIF2B. This switch dramatically reduces global translation initiation while selectively promoting translation of specific mRNAs containing upstream open reading frames, including those encoding transcription factors like ATF4 and CHOP[@zhao2018].
The eIF2α phosphorylation-mediated translational reprogramming serves an adaptive function in acute stress, allowing cells to conserve resources and redirect protein synthesis toward stress response programs. However, chronic eIF2α phosphorylation, as occurs in neurodegenerative diseases, has detrimental effects including impaired synaptic plasticity and memory consolidation. The role of eIF2α phosphorylation in memory consolidation is particularly relevant for Alzheimer's disease, where deficits in long-term memory are a hallmark symptom.
In neurons, PKR functions as a sentinel for various cellular stresses, coordinating the integrated stress response to maintain cellular homeostasis. Under normal conditions, PKR activity is kept low through autoinhibition. When activated by stress signals, PKR initiates the ISR, which can either promote adaptation and survival or, if stress persists, trigger apoptosis.
The ISR triggered by PKR activation has both protective and pathological effects depending on context and duration. Transient activation promotes stress adaptation and can enhance neuronal survival. However, chronic activation, as occurs in neurodegenerative diseases, leads to sustained translational repression that impairs synaptic function and ultimately contributes to neuronal death. This duality makes PKR a potential therapeutic target—modulating its activity may need to account for both beneficial and deleterious effects.
PKR and eIF2α phosphorylation have emerged as key regulators of synaptic plasticity and memory formation. Studies have shown that eIF2α phosphorylation is required for certain forms of long-term synaptic plasticity, including long-term depression (LTD)[@gal2011]. Paradoxically, while acute eIF2α phosphorylation is necessary for memory consolidation, chronic elevation impairs memory. This reflects the complex, biphasic relationship between eIF2α phosphorylation and cognitive function.
The role of PKR in synaptic plasticity extends beyond translational control. PKR can phosphorylate various synaptic proteins directly, including components of the postsynaptic density. PKR also interacts with signaling pathways involved in synaptic plasticity, including the MAPK/ERK and mTOR pathways. These diverse functions position PKR as a central regulator of activity-dependent synaptic changes that underlie learning and memory.
PKR is highly expressed in microglia, the resident immune cells of the brain, where it plays a major role in modulating neuroinflammatory responses. Microglial PKR activation by various stimuli leads to the production of pro-inflammatory cytokines including IL-1β, TNF-α, and IL-6. This inflammatory response can be protective in acute contexts but becomes pathological when chronic, as in neurodegenerative diseases.
The neuroinflammatory functions of PKR involve both cell-autonomous effects in microglia and non-cell-autonomous effects on neurons. PKR activation in microglia can lead to the release of neurotoxic factors that contribute to neuronal death. Additionally, inflammatory cytokines released from activated microglia can further activate PKR in neurons, creating a feed-forward loop of neuroinflammation and neurodegeneration[@bohle2017].
PKR has been strongly implicated in the tau pathology that characterizes [Alzheimer's disease](/diseases/alzheimers-disease). The kinase can phosphorylate tau directly at multiple sites that are hyperphosphorylated in AD brains, including sites associated with microtubule dissociation and aggregation. PKR-mediated tau phosphorylation promotes the formation of neurofibrillary tangles, one of the two hallmark lesions of AD[@huang2019].
Studies in animal models have confirmed the role of PKR in tau pathology. PKR deficiency in APP/PS1 mice reduces tau phosphorylation and improves cognitive function, despite continued amyloid deposition[@ocarroll2015]. Conversely, PKR overexpression exacerbates tau pathology and cognitive deficits. These findings establish PKR as a significant contributor to tau pathogenesis in AD.
PKR activation contributes to the synaptic dysfunction and memory impairment that characterize AD. The sustained eIF2α phosphorylation resulting from chronic PKR activation impairs the translational reprogramming required for long-term memory consolidation. PKR also affects synaptic function through direct phosphorylation of synaptic proteins and through effects on synaptic protein synthesis.
Clinical studies have confirmed PKR activation in AD brains, with increased PKR phosphorylation and eIF2α phosphorylation observed in affected regions including the hippocampus[@onken2017]. This activation correlates with cognitive impairment, supporting the clinical relevance of PKR-mediated pathology.
Neuroinflammation is a hallmark of AD, and PKR plays a central role in this process. In AD brains, PKR is activated in both neurons and microglia, contributing to the chronic neuroinflammatory state. Amyloid-beta plaques and oligomers can activate PKR directly, while the inflammatory milieu further stimulates PKR activation, creating a self-perpetuating cycle of neuroinflammation and neuronal dysfunction.
In [Parkinson's disease](/diseases/parkinsons-disease), PKR has been implicated in the aggregation and toxicity of alpha-synuclein, the protein that forms Lewy bodies in PD brains. Studies have shown that alpha-synuclein aggregates can activate PKR, while PKR activation in turn promotes alpha-synuclein aggregation and toxicity through multiple mechanisms[@yu2019]. This bidirectional relationship suggests that PKR contributes to the progressive aggregation of alpha-synuclein that characterizes PD.
PKR activation affects the survival of dopaminergic neurons, the cells that degenerate in PD. The kinase can promote both pro-survival and pro-death signaling depending on context, with chronic activation generally promoting death. PKR-mediated eIF2α phosphorylation can trigger the expression of pro-apoptotic factors, while PKR's effects on mitochondrial function and oxidative stress further influence neuronal survival.
Studies in PD models have shown that PKR inhibition can protect dopaminergic neurons from various insults, suggesting that PKR activation contributes to the selective vulnerability of these neurons in PD[@yang2020].
PKR activation has been documented in ALS and other motor neuron diseases, where it contributes to the characteristic degeneration of motor neurons. The kinase is activated in both neurons and glia in ALS, with activation driven by multiple stimuli including oxidative stress, mitochondrial dysfunction, and protein aggregates. PKR activation in ALS promotes neuroinflammation and translational dysregulation that contribute to motor neuron degeneration[@barcelona2018].
PKR activation can be assessed through measurement of phosphorylated PKR and eIF2α in cerebrospinal fluid and brain tissue. These markers are being evaluated for their potential to serve as diagnostic or prognostic biomarkers for neurodegenerative diseases. Elevated PKR activation has been observed in AD, PD, and ALS, though the specificity of this marker for individual diseases is limited.
Modulating PKR activity represents a potential therapeutic strategy for neurodegenerative diseases. Approaches being explored include:
Research on PKR in neurodegeneration employs various experimental approaches:
| Finding | Model System | Reference |
|---------|--------------|------------|
| PKR phosphorylates eIF2α | Recombinant proteins | [@dey2005] |
| PKR in neurodegeneration overview | Review | [@peel2011] |
| PKR deficiency reduces AD pathology | Mouse models | [@ocarroll2015] |
| PKR activated in AD and PD brains | Human tissue | [@onken2017] |
| PKR mediates tau phosphorylation | Cellular models | [@huang2019] |
| PKR in neuroinflammation | Microglia | [@bohle2017] |
| PKR in memory formation | Mouse models | [@gal2011] |
| PKR in ALS | Human tissue | [@barcelona2018] |